(CercleFinance.com) – Guerbet announces a slight decline in revenue of 0.7% to €179.8 million as of March 31, 2023. At constant exchange rates (CER), the specialist’s revenue contrast products and solutions for medical imaging fell by 1.3%.
After a start to the financial year that was still disrupted commercially by production delays, in Raleigh (North Carolina), the group nevertheless remains confident in its ability to meet its ambitions for the current financial year and the next.
For 2023, sales growth is expected to exceed 5% on a like-for-like basis and at constant exchange rates. Guerbet anticipates an EBITDA/restated revenue margin rate of around 11%, before a return from 2024 to a higher level than that seen in 2021 (14.4%).